Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.30 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL9389447 | 0.97 | CYP2D6 (0.34) | CYP2D6CYP2C19POLBCYP2C9KMT2A | |
| SCHEMBL7819308 | 0.83 | KDM4E (0.36) | POLBKMT2ACYP1A2ALDH1A1KDM4E | |
| Fosfocreatine SCHEMBL9073250 | 0.81 | — | — | |
| SCHEMBL17234253 | 0.80 | CYP2D6 (0.44) | CYP2D6CYP2C19POLBCYP2C9KMT2A | |
| SCHEMBL9889352 | 0.78 | INMT (0.37) | — | |
| SCHEMBL12535259 | 0.72 | LMNA (0.39) | CYP2D6CYP2C19POLBCYP2C9KMT2A | |
| SCHEMBL3070292 | 0.69 | CYP2D6 (0.37) | CYP2D6CYP2C19POLBCYP2C9KMT2A | |
| Cyclocreatine SCHEMBL446535 | 0.67 | TSHR (0.35) | CYP2D6CYP2C19POLBCYP2C9KMT2A | |
| SCHEMBL1981177 | 0.66 | CYP2D6 (0.69) | CYP2D6CYP2C19POLBCYP2C9KMT2A | |
| SCHEMBL17234207 | 0.66 | ACE (0.39) | CYP2D6CYP2C19POLBCYP2C9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230248751-A1 | NOVEL BIOENERGETIC/ANTI INFLAMMATORY THERAPY | NOUR HEART, INC. | 2023-08-10 | — | — | US | claimed |
| US-20240327437-A1 | DE NOVO Synthesis of Cyclocreatine and Subsequent Conversion to Cyclocreatine Phosphate Via a Continuous Flow Reactor (CFR) System | NOUR HEART, INC. | 2024-10-03 | — | — | US | disclosed |
| US-20240327437-A1 | DE NOVO Synthesis of Cyclocreatine and Subsequent Conversion to Cyclocreatine Phosphate Via a Continuous Flow Reactor (CFR) System | NOUR HEART, INC. | 2024-10-03 | — | — | US | disclosed |
| US-20240180912-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CREATINE TRANSPORT AS A TREATMENT FOR CANCER | INSPIRNA, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| US-11761966-B2 | Nourin gene-based RNA molecular network: novel early diagnostic and prognostic biomarkers for coronary artery disease, unstable angina, STEMI/NSTEMI and heart failure | NOUR HEART, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230248751-A1 | NOVEL BIOENERGETIC/ANTI INFLAMMATORY THERAPY | NOUR HEART, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230248751-A1 | NOVEL BIOENERGETIC/ANTI INFLAMMATORY THERAPY | NOUR HEART, INC. | 2023-08-10 | — | — | US | disclosed |
| US-11654134-B2 | Cyclocreatine phosphate: a novel bioenergetic therapy to prevent and treat ischemia-induced and aging-related cardiovascular and neurodegenerative diseases | NOUR HEART, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| WO-2023004308-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CREATINE TRANSPORT AS A TREATMENT FOR CANCER | INSPIRNA, INC. (US) | 2023-01-26 | — | — | WO | disclosed |
| US-20220241266-A1 | COMPOSITIONS AND METHODS USING TRIGONELLINE AND HIGH PROTEIN FOR PREVENTING OR TREATING CONDITIONS OR DISORDERS IN SKELETAL MUSCLE | NESTLE SA (CH) | 2022-08-04 | — | — | US | disclosed |
| EP-1065931-A1 | COMPOSITIONS CONTAINING A COMBINATION OF A CREATINE COMPOUND AND A SECOND AGENT | Avicena Group, Inc. (US) | 2001-01-10 | — | — | EP | disclosed |
| WO-1999051097-A1 | COMPOSITIONS CONTAINING A COMBINATION OF A CREATINE COMPOUND AND A SECOND AGENT | AVICENA GROUP, INC. (US) | 1999-10-14 | — | — | WO | disclosed |
| EP-0804183-A1 | USE OF CREATINE OR CREATINE ANALOGS FOR THE TREATMENT OF DISEASES OF THE NERVOUS SYSTEM | AVICENDA GROUP, INC. (US) | 1997-11-05 | — | — | EP | disclosed |
| WO-1996014063-A1 | USE OF CREATINE OR CREATINE ANALOGS FOR THE TREATMENT OF DISEASES OF THE NERVOUS SYSTEM | AVICENA GROUP, INC. (US) | 1996-05-17 | — | — | WO | disclosed |
| EP-0660709-A1 | CREATINE ANALOGS HAVING ANTIVIRAL ACTIVITY | AMIRA, INC. (US) | 1995-07-05 | — | — | EP | disclosed |
| WO-1994016712-A9 | CREATINE PHOSPHATE, CREATINE PHOSPHATE ANALOGS, AND USES THEREFOR | — | 1994-09-15 | — | — | WO | disclosed |
| WO-1994016712-A1 | CREATINE PHOSPHATE, CREATINE PHOSPHATE ANALOGS, AND USES THEREFOR | AMIRA, INC. (US) | 1994-08-04 | — | — | WO | disclosed |
| US-5321030-A | Administering for treatment or prevention | AMIRA, INC. (US) | 1994-06-14 | — | — | US | disclosed |
| WO-1993012781-A2 | CREATINE ANALOGS HAVING ANTIVIRAL ACTIVITY | AMIRA, INC. (US) | 1993-07-08 | — | — | WO | disclosed |
| WO-1992008456-A2 | METHOD OF INHIBITING TRANSFORMATION, GROWTH AND METASTASIS OF CELLS IN WHICH PURINE METABOLIC ENZYME ACTIVITY IS ELEVATED | AMIRA, INC. (US) | 1992-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240180912-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CREATINE TRANSPORT AS A TREATMENT FOR CANCER | KRAS, FOLR2, SLC19A1 | CYP2D6 2098/4885CYP2C19 2097/4885POLB 262/4885 |
| US-20220241266-A1 | COMPOSITIONS AND METHODS USING TRIGONELLINE AND HIGH PROTEIN FOR PREVENTING OR TREATING CONDITIONS OR DISORDERS IN SKELETAL MUSCLE | MUSK, TNNC1, CKMT1A; CKMT1B | CYP2D6 3466/4885CYP2C19 1689/4885POLB 4013/4885 |
| US-20240327437-A1 | DE NOVO Synthesis of Cyclocreatine and Subsequent Conversion to Cyclocreatine Phosphate Via a Continuous Flow Reactor (CFR) System | PCK1, PNKP, PFKFB4 | CYP2D6 983/4885CYP2C19 1264/4885POLB 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.